問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2025-10-18

黃意方
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

2Cases

2025-08-01 - 2032-12-31

Phase III

Active
AcTFirst: A phase III, open-label, multicenter, randomized trial comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration-resistant prostate cancer
  • Condition/Disease

    rPFS was defined as the time elapsed from the date of randomization to the date of the first documented radiographic disease progression or death from any cause as assessed by the Blinded Independent Central Review Committee (BICR) using conventional imaging and Prostate Cancer Working Group 3 (PCWG3) revised RECIST version 1.1 criteria, whichever occurred first.

  • Test Drug

    AAA617 AAA817 Abiraterone Cabazitaxel

Participate Sites
5Sites

Recruiting5Sites

2025-05-01 - 2029-03-06

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites